GlobeNewswire by notified

Continued strong results in the first quarter of 2023

Share

(Oslo, Norway, 23 May 2023)Statkraft delivered strong results in the first quarter of 2023, with solid operations in all geographies and continued strong performance in Markets. Statkraft realised a gain of NOK 1.6 billion after selling half of its offshore wind portfolio in Ireland.

  • Net operating revenues rose to NOK 24.5 billion from NOK 22.1 billion in Q1 2022, while underlying EBIT increased to NOK 18.5 billion (NOK 18.0 billion), Statkraft’s second strongest quarter ever.
  • Power prices were somewhat lower in general, but prices increased in northern Norway and Sweden.
  • Statkraft and Skagerak Energitjenester were first to offer new and more customised fixed-price power contracts to Norwegian businesses in early May.
  • Statkraft signed its first long-term power purchase agreement (PPA) in the US, as well as several new PPAs and power supply agreements (PSAs) in Norway, Italy and Poland.

"High power prices, though at a lower level than last year, combined with solid operations gave very strong results from power production. Value-creation in Markets continued to be very strong,” says Statkraft CEO, Christian Rynning-Tønnesen.

The Group operating revenues were significantly impacted by positive contributions from hedging and currency effects due to the weakening of the Norwegian krone.

Operating expenses increased, driven primarily by the high-price contribution in Norway, a weakening of the Norwegian krone and a higher number of employees as the company continues on its growth strategy. The underlying costs for existing operations were stable.

Net financials were negatively impacted by the weakening of the NOK. After taxes of NOK 10.4 billion, net result ended at a solid NOK 10.9 billion.

In January Statkraft sold 50 per cent of our 2200 MW offshore wind power portfolio in Ireland to Copenhagen Infrastructure Partners (CIP), a global leader in renewable energy investments. Statkraft realised a gain of NOK 1.6 billion from the sale. The two companies plan to invest more than NOK 40 billion in offshore wind projects in Ireland.

“The partnership with CIP demonstrates our value-creation potential within offshore wind and our ambition to pursue an industrial role in Ireland and the North Sea. We continue to develop our project portfolio and expand our organisation to support the ambitious green growth strategy to develop much needed renewable energy in Norway and internationally", Rynning-Tønnesen adds.

Statkraft’s ambition is to become a leading global renewable energy producer, building 2500-3000 MW per year, increasing to around 4000 MW every year by 2030. The majority of new investments will be within onshore wind, solar and hydropower. In hydropower, Statkraft plans to start five major capacity upgrade projects in Norway by 2030 to balance the increasing amounts of intermittent wind power generation.

For further information, please contact:

Debt Capital Markets:
Vice President Stephan Skaane, tel: +47 905 13 652, e-mail: stephan.skaane@statkraft.com
Senior Financial Advisor Arild Ratikainen, tel: +47 971 74 132, e-mail: arild.ratikainen@statkraft.com

Media:
Vice President Torbjørn Steen, tel: +47 911 66 888, e-mail: torbjorn.steen@statkraft.com
Head advisor Lars Magnus Günther, tel: +47 912 41 636, e-mail: lars.gunther@statkraft.com

or www.statkraft.com

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

About Statkraft
Statkraft is a leading company in hydropower internationally and Europe’s largest generator of renewable energy. The Group produces hydropower, wind power, solar power, gas-fired power and supplies district heating. Statkraft is a global company in energy market operations. Statkraft has 5.300 employees in 21 countries.

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

RevoluGROUP Announces CEO and Director Stepping Down3.5.2024 00:25:00 CEST | Press release

VANCOUVER, British Columbia and BARCELONA, Spain., May 02, 2024 (GLOBE NEWSWIRE) -- RevoluGROUP Canada Inc. (TSX- V: REVO), (Frankfurt: IJA2), (Munich: A2PU92) ("RevoluGROUP") today announced CEO and Director, Gavin McMillan, will be stepping down from his positions, effective immediately. Gavin joined the Company in August 2023 and served as CEO for over six months. During his leadership, McMillan has been instrumental in focusing on the continued development of the API-driven Payment-as-a-Service (PaaS) model, which has continued to expand through key white-label partnerships and joint venture agreements and enhancing revenue streams. In a statement, Bernard Lonis, the Chairman of the Board, acknowledged McMillan's vital contributions and leadership, stating, "We owe a great deal of gratitude to Gavin for his dedication and the continued strong foundation he has helpedtobuildforRevoluGROUP'sfuture. We wish Gavin the best in his future endeavors." The Board has commenced a comprehensi

Novotech Appoints Commercial and Clinical Life Sciences Specialist to Head Up Global Drug Development Consulting Team2.5.2024 23:00:15 CEST | Press release

BOSTON, May 02, 2024 (GLOBE NEWSWIRE) -- Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has appointed Scott Schliebner as Vice President and Global Head, Drug Development Consulting (DDC). Novotech’s Chief Medical Officer Dr. Judith Ng-Cashin stated: “We welcome Scott to the medical and scientific team. He is a proven strategic, innovative, and business focused life sciences executive with ~30 year of experience across the biopharma and CRO sectors. He brings valuable leadership to our world-class DDC team, a full-service global drug development and strategic regulatory team providing comprehensive "inception to approval" services.” The DDC partners with biotechs to optimize a fit-for purpose therapeutic development strategy that both advances the development program and creates value for the company. To do this, DDC leverages CMC/manufa

Brookfield Reinsurance Completes Acquisition of AEL2.5.2024 22:10:00 CEST | Press release

BROOKFIELD, NEWS, May 02, 2024 (GLOBE NEWSWIRE) -- Brookfield Reinsurance (NYSE, TSX: BNRE, BNRE.A) and American Equity Investment Life Holding Company (NYSE: AEL) (“AEL”) today announced the completion of Brookfield Reinsurance’s acquisition of AEL in a cash and stock transaction valued at $56.50 per AEL share. AEL’s leading fixed annuity business bolsters Brookfield Reinsurance’s expanding insurance operations and increases its insurance assets under management to over $100 billion. Jon Bayer, Managing Partner at Brookfield Reinsurance said, “We are excited to welcome AEL to our organization as we continue to grow, diversify and scale our retirement services capabilities. AEL’s strong franchise and track record of serving policyholders and distribution partners, coupled with the scale of our existing platform and offerings, will position us well for the next phase of growth.” Brookfield Reinsurance expects to maintain AEL’s headquarters in Des Moines, Iowa, and its growth in the fixe

Fortinet Reports First Quarter 2024 Financial Results2.5.2024 22:05:43 CEST | Press release

First Quarter 2024 Highlights Total revenue of $1.35 billion, up 7% year over yearService revenue of $944 million, up 24% year over yearGAAP operating margin of 23.7%Non-GAAP operating margin of 28.5%1Cash flow from operations of $830 millionFree cash flow of $609 million1 SUNNYVALE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Fortinet® (Nasdaq: FTNT), a global cybersecurity leader driving the convergence of networking and security, today announced financial results for the first quarter ended March 31, 2024. “We are diligently executing on our strategy announced six months ago to leverage our scale, go-to-market capabilities, customer-first focus, and engineering expertise to capitalize on the fast-growing Unified SASE and Security Operations markets while continuing to gain market share in Secure Networking,” said Ken Xie, Founder, Chairman and Chief Executive Officer of Fortinet. “We believe our Unified SASE offering is the most comprehensive in the industry and we are well-positioned

Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results2.5.2024 22:05:00 CEST | Press release

Reported $420.5 million in cash resources as of March 31, 2024, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027Completion of rolling biologics license application (BLA) filing with the U.S. Food and Drug Administration (FDA) for zanidatamab as second-line treatment for biliary tract cancers (BTC) in the United States (U.S.) by our partner, Jazz PharmaceuticalsExpected initiation of a Phase 3 clinical trial for zanidatamab in the second half of 2024, for breast cancer patients who have progressed on trastuzumab deruxtecan (T-DXd), by our partner, Jazz Pharmaceuticals Two planned investigational new drug (IND) and foreign equivalent submissions in 2024 for ZW191 and ZW171Acceptance of an abstract for zanidatamab in BTC at the American Society of Clinical Oncology (ASCO) annual meeting submitted by our partner, Jazz PharmaceuticalsPresentation of five abstracts at the American Association for Cancer Research (AACR) ann

HiddenA line styled icon from Orion Icon Library.Eye